TelyRx Holdings Inc. faced a significant drop in its stock price today, reflecting investor concerns.
In the latest trading session, TelyRx Holdings Inc. (TELY.TO) saw its stock plummet by 7.14%, closing at CA$2.60. This decline raises questions about the company's market performance and future prospects.
Investor takeaway: Investors should closely monitor TelyRx's financial health and market position, especially in light of today's significant price drop.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$74.42M
52W high
$4.25
52W low
$2.00
1W change
+12.00%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 114.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+114.3% Upside
Current Price
C$2.80
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
103.2%
Annualized
90-Day Vol
99.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.34
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.64 | C$1.85 โ C$3.77 |
| 60 trading days | C$2.49 | C$1.50 โ C$4.11 |
| 90 trading days | C$2.34 | C$1.26 โ C$4.34 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
TelyRx Holdings Inc. down 7.14% in one trading day
With a market cap of CA$74.4 million and a closing price of CA$2.60, TelyRx's recent performance highlights investor skepticism.
Bull case
TelyRx has shown promise with its digital pharmacy services, recently surpassing one million prescriptions. This milestone suggests thereโs growing demand for its offerings, which could lead to future growth.
Bear case
The recent decline in stock price, along with ongoing net losses, indicates that investors may be losing confidence in TelyRx's ability to turn a profit.
Market Reaction and Investor Sentiment
The 7.14% drop in TelyRx's stock price today reflects a broader concern among investors regarding the company's financial performance. Despite recent milestones, such as surpassing one million prescriptions, the lack of profitability remains a significant hurdle. Investors are likely reassessing their positions in light of the company's ongoing net losses.
Future Outlook for TelyRx
As TelyRx continues to expand its operations and services, the focus will be on how effectively it can convert growth into profitability. The recent financial results indicate a revenue increase, but the persistent net losses raise questions about sustainability. Investors should keep an eye on upcoming earnings reports and strategic initiatives that may influence future performance. For more insights, visit the TelyRx stock page.
Advertisement
